Search

Your search keyword '"Cancer"' showing total 1,217,141 results
Start Over Author "Cancer"

Refine your results

more »

more »

more »

more »

more »

more »

more »

more »
1,217,141 results on '"Cancer"'

1. Chinese expert consensus on whole-process management of oxaliplatin-induced hypersensitivity reactions (2024 edition)

Author

Cancer Assessment Society of China Anti-Cancer Association, Cancer Pain Society of Fujian Anti-Cancer Association

Subjects
anti-cancer treatment, oxaliplatin, rapid hypersensitivity reactions, rapid desensitization, consensus, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Oxaliplatin serves as a basic therapeutic agent for various malignant tumors. Oxaliplatin-induced hypersensitivity reactions are potentially life-threatening, and frequently lead to treatment discontinuation. Alternative therapies may be less effective and/or more expensive, with varying tolerability. Oxaliplatin hypersensitivity reactions typically manifest as a classic type Ⅰ allergy, as well as cytokine release reactions and mixed types. In clinical practice, management of anaphylaxis and questions relative to rechallenge with oxaliplatin after occurrence of hypersensitivity reactions are of utmost concern. Therefore, based on evidence-based medicine and clinical practice experience, the expert panel carried out a comprehensive assessment and discussion on the definition, clinical characteristics, diagnosis, classification and grading criteria, management, and rechallenge of hypersensitivity reactions to oxaliplatin. Eventually, the "Chinese expert consensus on whole-process management of oxaliplatin-induced hypersensitivity reactions (2024 edition)" was formulated to further standardize the whole-process management of oxaliplatin-induced hypersensitivity reactions. The consensus has been registered on Practice guideline REgistration for transPAREncy (PREPARE) with the registration number PREPARE-2024CN371.

Published
2024
Full Text
View/download PDF

2. Expert consensus of 177Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)

Author

Cancer Nuclear Medicine Committee of China Anti-Cancer Association, Chinese Association of Nuclear Medicine Physicians

Subjects
177lu-labeled prostate-specific membrane antigen radioligand therapy, prostate cancer, clinical practice, expert consensus, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

177Lu-labeled prostate-specific membrane antigen radioligand therapy (177Lu-PSMA-RLT) is an innovative treatment approach that precisely delivers β radiation emitted by 177Lu to prostate cancer cells, causing radiation damage to the tumor cells’ DNA and thereby eliminating the tumor. At present, it has been recommended for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) by many international and national authoritative guidelines and consensuses. However, there are no published clinical practice path and medication specifications for diagnosis and treatment in China. Therefore, the consensus was jointly initiated by Cancer Nuclear Medicine Committee of Chinese Anti-Cancer Association and Chinese Association of Nuclear Medicine Physicians. Physicians from these two committees combined the existing results of 177Lu-PSMA-RLT registration study, real world data domestic and international clinical experience of radionuclide treatment, and gave recommendations in terms of indications, screening adverse reactions, follow-up and radiation safety by taking different levels of evidence as reference according to clinical evidence levels and grades of recommendation from the Oxford Centre for Evidence-based Medicine. The purpose of this consensus was to provide physicians with reference for clinical application in the practice of 177Lu-PSMA-RLT for the treatment of prostate cancer based on existing evidence and lay the foundation for the development of subsequent industry-related guidelines.

Published
2024
Full Text
View/download PDF

3. Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)

Author

Cancer Rehabilitation and Palliative Professional Committee of Shanghai Anti-Cancer Association , Cancer Drug Clinical Research Committee of Shanghai Anti-Cancer Association , Cancer Prevention and Clinical Research Committee of Chinese Aging Well Association

Subjects
antineoplastic, nausea, vomiting, whole-process management, consensus, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Nausea and vomiting are common adverse reactions in tumor patients during anti-tumor therapy such as chemotherapy, radiotherapy, targeted therapy and immunotherapy. Although chemotherapy-induced nausea and vomiting (CINV) is the most common and the most intensively studied adverse event, radiation-induced nausea and vomiting (RINV), targeted therapy and immunotherapy-induced nausea and vomiting (TIINV) have also attracted more and more attention. Based on “Shanghai expert consensus on whole-process management of chemotherapy-induced nausea and vomiting (2018 edition)”, as well as new medical evidence of antineoplastic-induced nausea and vomiting (AINV) and experience of Shanghai experts in this field, the expert group finally developed “Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)”. This consensus will guide doctors in Shanghai to standardize the whole-process management of AINV, and to ensure the treatment intensity and medical safety of patients.

Published
2024
Full Text
View/download PDF

4. Combining fecal immunochemical testing and questionnaire-based risk assessment in selecting participants for colonoscopy screening in the Chinese National Colorectal Cancer Screening Programs: A population-based cohort study.

Author

Xuesi Dong, Lingbin Du, Zilin Luo, Yongjie Xu, Chenran Wang, Fei Wang, Wei Cao, Liang Zhao, Yadi Zheng, Hongting Zhu, Changfa Xia, Jiang Li, Mulong Du, Dong Hang, Jiansong Ren, Jufang Shi, Hongbing Shen, Wanqing Chen, Ni Li, Jie He, and Cancer Screening Program in Urban China (CanSPUC) Group

Subjects
Medicine
Abstract

BackgroundScreening reduces colorectal cancer (CRC) burden by allowing early resection of precancerous and cancerous lesions. An adequate selection of high-risk individuals and a high uptake rate for colonoscopy screening are critical to identifying people more likely to benefit from screening and allocating healthcare resources properly. We evaluated whether combining a questionnaire-based interview for risk factors with fecal immunochemical test (FIT) outcomes for high-risk assessment is more efficient and economical than a questionnaire-based interview-only strategy.Methods and findingsIn this multicenter, population-based, prospective cohort study, we enrolled community residents aged 40 to 74 years in 29 provinces across China. From 2016 to 2020, a total of 1,526,824 eligible participants were consecutively enrolled in the Cancer Screening Program in Urban China (CanSPUC) cohort, and 940,605 were enrolled in the Whole Life Cycle of Cancer Screening Program (WHOLE) cohort, with follow-up to December 31, 2022. The mean ages were 56.89 and 58.61 years in CanSPUC and WHOLE, respectively. In the WHOLE cohort, high-risk individuals were identified by combining questionnaire-based interviews to collect data on risk factors (demographics, diet history, family history of CRC, etc.) with FIT outcomes (RF-FIT strategy), whereas in the CanSPUC cohort, high-risk individuals were identified using only interview-based data on risk factors (RF strategy). The primary outcomes were participation rate and yield (detection rate of advanced neoplasm, early-stage detection rate of CRCs [stage I/II], screening yield per 10,000 invitees), which were reported for the entire population and for different gender and age groups. The secondary outcome was the cost per case detected. In total, 71,967 (7.65%) and 281,985 (18.47%) individuals were identified as high-risk and were invited to undergo colonoscopy in the RF-FIT group and RF group, respectively. The colonoscopy participation rate in the RF-FIT group was 26.50% (19,071 of 71,967) and in the RF group was 19.54% (55,106 of 281,985; chi-squared test, p < 0.001). A total of 102 (0.53%) CRCs and 2,074 (10.88%) advanced adenomas were detected by the RF-FIT, versus 90 (0.16%) and 3,593 (6.52%) by the RF strategy (chi-squared test, both p < 0.001). The early-stage detection rate using the RF-FIT strategy was significantly higher than that by the RF strategy (67.05% versus 47.95%, Fisher's exact test, p = 0.016). The cost per CRC detected was $24,849 by the RF-FIT strategy versus $55,846 by the RF strategy. A limitation of the study was lack of balance between groups with regard to family history of CRC (3.5% versus 0.7%).ConclusionsColonoscopy participation and screening yield were better with the RF-FIT strategy. The association with CRC incidence and mortality reduction should be evaluated after long-term follow-up.

Published
2024
Full Text
View/download PDF

5. Expert consensus on the clinical application of antibody‐drug conjugates in the treatment of malignant tumors (2021 edition)

Author

Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti‐Cancer Association, Expert Committee for Monitoring the Clinical Application of Antitumor Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, and Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center

Subjects
malignant tumors, antibody‐drug conjugates, monoclonal antibodies, cytotoxic drugs, safety management, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Antibody‐drug conjugates (ADCs) are targeted biological agents composed of a cytotoxic drug linked to a monoclonal antibody through a linker. The monoclonal antibody targets tumor cells and transports small‐molecule cytotoxic drugs for specific delivery and minimal off‐target side effects. It is necessary for clinicians to understand the molecular characteristics and mechanisms of ADCs. Patients' survival mainly depends on the appropriate dose and course of treatment and also on proper management of adverse reactions. This consensus provides a systematic review of commercially available ADCs and further discusses the clinical application and management of ADCs.

Published
2022
Full Text
View/download PDF

7. A Prospective, Non-interventional Cohort Study of Subsolid Pulmonary Nodules

Author

Third Affiliated Hospital, Sun Yat-Sen University, Fifth Affiliated Hospital, Sun Yat-Sen University, Peking University People's Hospital, Guangxi Medical University, Shanghai Zhongshan Hospital, The Third Xiangya Hospital of Central South University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, The Third People's Hospital of Chengdu, Shantou Central Hospital, Hainan Cancer Hospital, Shenzhen People's Hospital, Hunan Cancer Hospital, Shenzhen Third People's Hospital, First Affiliated Hospital of Jinan University, Haikou People's Hospital, Second Affiliated Hospital of Guangzhou Medical University, and Xue-Ning Yang, Vice-Chief of Guangdong Lung Cancer Institute

Published
2024

9. Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Author

Intergroupe Francophone de Cancerologie Thoracique, Thoracic Oncology Group of Australasia (TOGA), National Health and Medical Research Council, Australia, National Cancer Institute (NCI), Naples, Central and Eastern European Oncology Group, Dutch Society of Physicians for Pulmonology and Tuberculosis, Korean Cancer Study Group, Fundación GECP, West Japan Oncology Group (WJOG), and Chinese Thoracic Oncology Group

Published
2024

15. Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Author

Southwest Hospital, China, Women Hospital, School of Medicine, Zhejiang University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Qilu Hospital of Shandong University, Beijing Friendship Hospital, Tianjin Medical University General Hospital, West China Second University Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Xiangya Hospital of Central South University, Gansu Provincial Maternal and Child Health Care Hospital, Zhejiang Cancer Hospital, Shengjing Hospital, Cancer Hospital of Guangxi Medical University, and Kezhen Li, Prof

Published
2024

16. Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Author

Southwest Hospital, China, Women Hospital, School of Medicine, Zhejiang University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Gansu Provincial Maternal and Child Health Care Hospital, Beijing Friendship Hospital, Tianjin Medical University General Hospital, Xiangya Hospital of Central South University, West China Second University Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhejiang Cancer Hospital, Shengjing Hospital, Qilu Hospital of Shandong University, Cancer Hospital of Guangxi Medical University, and Kezhen Li, Prof

Published
2024

17. Bright IDEAS - Young Adults Problem-Solving Skills Training

Author

National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, University of Rochester, and Katie Devine, PhD, MPH, Assistant Professor Pediatrics

Published
2024

19. Phase I/II Clinical Trial of LBL-015 for Injection

Author

Shanghai East Hospital, Shandong Cancer Hospital and Institute, Henan Cancer Hospital, Hunan Cancer Hospital, The First Affiliated Hospital of Nanchang University, and First Affiliated Hospital Bengbu Medical College

Published
2024

23. T2* MRI Analysis for Sarcoma

Author

Holden Comprehensive Cancer Center, National Cancer Institute (NCI), and Bryan Allen, Assistant Professor

Published
2024

27. CD30 CAR for CD30+ NSGCT

Author

University Cancer Research Fund at Lineberger Comprehensive Cancer Center

Published
2024

35. Meaning-Centered Psychotherapy Training for Cancer Care Providers

Author

Stanford University, Northwestern University, MJHS Institute for Innovation in Palliative Care, Massachusetts General Hospital, City of Hope Medical Center, Dana-Farber Cancer Institute, New York Presbyterian Hospital, Odette Cancer Center - Sunnybrook Hospital, VA New York Harbor Healthcare System, University of Pennsylvania, Smilow Cancer Hospital - Yale New Haven Health, Department of Veterans Affairs, New Jersey, and Vidant Cancer Care

Published
2024

46. High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma (SARveillance)

Author

University of Birmingham, University Hospital Birmingham NHS Foundation Trust, Royal Marsden NHS Foundation Trust, University Hospital Padova, Campus Bio-Medico University, The Netherlands Cancer Institute, KU Leuven, Heidelberg University, Dana-Farber/Brigham and Women's Cancer Center, Emory University, Mayo Clinic, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, The Cleveland Clinic, M.D. Anderson Cancer Center, University of Southern California, Ohio State University, Ottawa Hospital Research Institute, McGill University, Peter MacCallum Cancer Centre, Australia, and Royal Prince Alfred Hospital, Sydney, Australia

Published
2024

48. PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer (PAROLA)

Author

ARCAGY/ GINECO GROUP, European Network of Gynaecological Oncological Trial Groups (ENGOT), Gynecologic Cancer Intergroup (GCIG), Grupo Español de Investigación en Cáncer de Ovario, Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies, Belgian Gynaecological Oncology Group, Swiss GO Trial Group, Institute of Cancer Research, United Kingdom, The Central and Eastern European Gynecologic Oncology Group, and Hellenic Cooperative Oncology Group

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results